List of monoclonal antibodies

From Wikipedia, the free encyclopedia
Jump to: navigation, search

This is a list of therapeutic, diagnostic and preventive monoclonal antibodies, antibodies which are clones of a single parent cell. When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies.

Types of monoclonal antibodies with other structures than naturally occurring antibodies.

The abbreviations in the column Type are as follows:

This list includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage.

Name Trade name Type Source Target Use
3F8  ? mouse GD2 neuroblastoma
8H9[1] mab mouse IgG1 "human brain cancers"
Abagovomab[2] mab mouse CA-125 (imitation) ovarian cancer
Abciximab ReoPro Fab chimeric CD41 (integrin alpha-IIb) platelet aggregation inhibitor
Adalimumab Humira mab human TNF-α Rheumatoid arthritis, Crohn's Disease, Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis
Adecatumumab[3] mab human EpCAM prostate and breast cancer
Afelimomab F(ab')2 mouse TNF-α sepsis
Afutuzumab[4] mab humanized CD20 lymphoma
Alacizumab pegol[5] F(ab')2 humanized VEGFR2 cancer
ALD518[6]  ? humanized IL-6 rheumatoid arthritis
Alemtuzumab[7] Campath, MabCampath mab humanized CD52 CLL, CTCL
Altumomab pentetate Hybri-ceaker mab mouse CEA colorectal cancer (diagnosis)
Amatuximab[8] mab chimeric MORAb-009 cancer
Anatumomab mafenatox Fab mouse TAG-72 non-small cell lung carcinoma
Anrukinzumab[5] (= IMA-638)[9] mab humanized IL-13  ?
Apolizumab[10] mab humanized HLA-DR ? hematological cancers
Arcitumomab CEA-Scan Fab' mouse CEA gastrointestinal cancers (diagnosis)
Aselizumab[11] mab humanized L-selectin (CD62L) severely injured patients
Atinumab[12] mab human RTN4  ?
Atlizumab (= tocilizumab) Actemra, RoActemra mab humanized IL-6 receptor rheumatoid arthritis
Atorolimumab mab human Rhesus factor hemolytic disease of the newborn[citation needed]
Bapineuzumab[13] mab humanized beta amyloid Alzheimer's disease
Basiliximab Simulect mab chimeric CD25 (α chain of IL-2 receptor) prevention of organ transplant rejections
Bavituximab[2] mab chimeric phosphatidylserine cancer, viral infections
Bectumomab LymphoScan Fab' mouse CD22 non-Hodgkin's lymphoma (detection)
Belimumab Benlysta, LymphoStat-B mab human BAFF non-Hodgkin lymphoma etc.
Benralizumab mab humanized CD125 asthma
Bertilimumab[11] mab human CCL11 (eotaxin-1) severe allergic disorders
Besilesomab[14] Scintimun mab mouse CEA-related antigen inflammatory lesions and metastases (detection)
Bevacizumab[7] Avastin mab humanized VEGF-A metastatic cancer
Biciromab FibriScint Fab' mouse fibrin II, beta chain thromboembolism (diagnosis)
Bivatuzumab mertansine mab humanized CD44 v6 squamous cell carcinoma
Blinatumomab BiTE mouse CD19 cancer
Blosozumab[15] mab humanized SOST osteoporosis
Brentuximab vedotin[16] mab chimeric CD30 (TNFRSF8) hematologic cancers
Briakinumab[17] mab human IL-12, IL-23 psoriasis, rheumatoid arthritis, inflammatory bowel diseases, multiple sclerosis
Brodalumab[18] mab human IL-17 inflammatory diseases
Canakinumab[19] Ilaris mab human IL-1? rheumatoid arthritis
Cantuzumab mertansine mab humanized mucin CanAg colorectal cancer etc.
Cantuzumab ravtansine[15] mab humanized MUC1 cancers
Caplacizumab[20] mab humanized VWF  ?
Capromab pendetide Prostascint mab mouse prostatic carcinoma cells prostate cancer (detection)
Carlumab[21] mab human CNTO888 oncology/immune indications
Catumaxomab[13] Removab 3funct rat/mouse hybrid EpCAM, CD3 ovarian cancer, malignant ascites, gastric cancer
CC49 mab mouse TAG-72 tumor detection
Cedelizumab mab humanized CD4 prevention of organ transplant rejections, treatment of autoimmune diseases
Certolizumab pegol[3] Cimzia Fab' humanized TNF-α Crohn's disease
Cetuximab Erbitux mab chimeric EGFR metastatic colorectal cancer and head and neck cancer
Ch.14.18 [1] mab chimeric  ??? neuroblastoma
Citatuzumab bogatox[4] Fab humanized EpCAM ovarian cancer and other solid tumors
Cixutumumab mab human IGF-1 receptor solid tumors
Clenoliximab mab chimeric CD4 rheumatoid arthritis
Clivatuzumab tetraxetan[22] hPAM4-Cide mab humanized MUC1 pancreatic cancer
Conatumumab[4] mab human TRAIL-R2 cancer
Crenezumab[23] mab humanized MABT5102A Alzheimer's disease
CR6261 mab human Influenza A hemagglutinin infectious disease/influenza A
Dacetuzumab[5] mab humanized CD40 hematologic cancers
Daclizumab Zenapax mab humanized CD25 (α chain of IL-2 receptor) prevention of organ transplant rejections
Dalotuzumab[24] mab humanized insulin-like growth factor I receptor cancer etc.
Daratumumab[25] mab human CD38 (cyclic ADP ribose hydrolase)  ?
Denosumab[26] Prolia mab human RANKL osteoporosis, bone metastases etc.
Detumomab mab mouse B-lymphoma cell lymphoma
Dorlimomab aritox[27] F(ab')2 mouse  ?  ?
Drozitumab[28] mab human DR5 cancer etc.
Ecromeximab[10] mab chimeric GD3 ganglioside malignant melanoma
Eculizumab[10] Soliris mab humanized C5 paroxysmal nocturnal hemoglobinuria
Edobacomab mab mouse endotoxin sepsis caused by Gram-negative bacteria
Edrecolomab Panorex mab mouse EpCAM colorectal carcinoma
Efalizumab[29] Raptiva mab humanized LFA-1 (CD11a) psoriasis (blocks T-cell migration)
Efungumab[2] Mycograb scFv human Hsp90 invasive Candida infection
Elotuzumab mab humanized SLAMF7 multiple myeloma
Elsilimomab mab mouse IL-6  ?
Enavatuzumab[30] mab humanized PDL192 cancer etc.
Enlimomab pegol[31] mab mouse ICAM-1 (CD54)  ?
Enokizumab[32] mab humanized MEDI-528 asthma
Ensituximab[33] mab chimeric NPC-1C cancer
Epitumomab cituxetan[34] mab mouse episialin  ?
Epratuzumab mab humanized CD22 cancer, SLE
Erlizumab[35] F(ab')2 humanized ITGB2 (CD18) heart attack, stroke, traumatic shock
Ertumaxomab[13] Rexomun 3funct rat/mouse hybrid HER2/neu, CD3 breast cancer etc.
Etaracizumab Abegrin mab humanized integrin αvβ3 melanoma, prostate cancer, ovarian cancer etc.
Etrolizumab[36] mab humanized rhuMAb β7 inflammatory bowel disease
Exbivirumab[37] mab human hepatitis B surface antigen hepatitis B
Fanolesomab[38] NeutroSpec mab mouse CD15 appendicitis (diagnosis)
Faralimomab mab mouse interferon receptor  ?
Farletuzumab mab humanized folate receptor 1 ovarian cancer
FBTA05[39][40] Lymphomun 3funct rat/mouse hybrid CD20 chronic lymphocytic leukaemia
Felvizumab mab humanized respiratory syncytial virus respiratory syncytial virus infection
Fezakinumab[41][42][43] mab human IL-22 rheumatoid arthritis, psoriasis
Ficlatuzumab[44] mab humanized SCH 900105 cancer etc.
Figitumumab mab human IGF-1 receptor adrenocortical carcinoma, non-small cell lung carcinoma etc.
Flanvotumab[45] mab human glycoprotein 75 melanoma
Fontolizumab[10] HuZAF mab humanized IFN-γ Crohn's disease etc.
Foralumab[46] mab human CD3 epsilon  ?
Foravirumab[4] mab human rabies virus glycoprotein rabies (prophylaxis)
Fresolimumab[47] mab human TGF-β idiopathic pulmonary fibrosis, focal segmental glomerulosclerosis, cancer
Fulranumab[48] mab human NGF pain
Galiximab mab chimeric CD80 B-cell lymphoma
Ganitumab[49] mab human IGF-I cancer
Gantenerumab[19] mab human beta amyloid Alzheimer's disease
Gavilimomab[35] mab mouse CD147 (basigin) graft versus host disease
Gemtuzumab ozogamicin Mylotarg mab humanized CD33 acute myelogenous leukemia
Gevokizumab[50] mab humanized IL-1β diabetes etc.
Girentuximab[25] Rencarex mab chimeric carbonic anhydrase 9 (CA-IX) clear cell renal cell carcinoma[51]
Glembatumumab vedotin[52][53] mab human GPNMB melanoma, breast cancer
Golimumab[37] Simponi mab human TNF-α rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis
Gomiliximab mab chimeric CD23 (IgE receptor) allergic asthma
GS6624 [54] mab  ?  ? idiopathic pulmonary fibrosis and solid tumors
Ibalizumab[19] mab humanized CD4 HIV infection
Ibritumomab tiuxetan Zevalin mab mouse CD20 non-Hodgkin's lymphoma
Icrucumab[55] mab human VEGFR-1 cancer etc.
Igovomab Indimacis-125 F(ab')2 mouse CA-125 ovarian cancer (diagnosis)
Imciromab Myoscint mab mouse cardiac myosin cardiac imaging
Inclacumab[20] mab human selectin P  ?
Indatuximab ravtansine[15] mab chimeric SDC1 cancer
Infliximab Remicade mab chimeric TNF-α rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn's disease, ulcerative colitis
Intetumumab[56][57][58] mab human CD51 solid tumors (prostate cancer, melanoma)
Inolimomab mab mouse CD25 (α chain of IL-2 receptor) graft versus host disease
Inotuzumab ozogamicin[14] mab humanized CD22 cancer
Ipilimumab[26] Yervoy mab human CD152 melanoma
Iratumumab[26] mab human CD30 (TNFRSF8) Hodgkin's lymphoma
Itolizumab[46] mab humanized CD6  ?
Ixekizumab[59] mab humanized IL-17A autoimmune diseases
Keliximab mab chimeric CD4 chronic asthma
Labetuzumab[29] CEA-Cide mab humanized CEA colorectal cancer
Lebrikizumab[60] mab humanized IL-13 asthma
Lemalesomab[35] mab mouse NCA-90 (granulocyte antigen) diagnostic agent
Lerdelimumab[7] mab human TGF beta 2 reduction of scarring after glaucoma surgery
Lexatumumab[2] mab human TRAIL-R2 cancer
Libivirumab[37] mab human hepatitis B surface antigen hepatitis B
Lintuzumab mab humanized CD33 cancer
Lorvotuzumab mertansine mab humanized CD56 cancer
Lucatumumab[5] mab human CD40 multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's lymphoma
Lumiliximab[3] mab chimeric CD23 (IgE receptor) chronic lymphocytic leukemia
Mapatumumab[13] mab human TRAIL-R1 cancer
Maslimomab  ? mouse T-cell receptor  ?
Mavrilimumab[61] mab human CAM-3001 rheumatoid arthritis
Matuzumab[11] mab humanized EGFR colorectal, lung and stomach cancer
Mepolizumab Bosatria mab humanized IL-5 asthma and white blood cell diseases
Metelimumab[38] mab human TGF beta 1 systemic scleroderma
Milatuzumab[5] mab humanized CD74 multiple myeloma and other hematological malignancies
Minretumomab mab mouse TAG-72  ?
Mitumomab mab mouse GD3 ganglioside small cell lung carcinoma
Mogamulizumab[62] mab humanized CCR4 cancer
Morolimumab mab human Rhesus factor  ?
Motavizumab[2] Numax mab humanized respiratory syncytial virus respiratory syncytial virus (prevention)
Moxetumomab pasudotox[63] mab mouse CD22 cancer
Muromonab-CD3 Orthoclone OKT3 mab mouse CD3 prevention of organ transplant rejections
Nacolomab tafenatox Fab mouse C242 antigen colorectal cancer
Namilumab[12] mab human CSF2  ?
Naptumomab estafenatox[64] Fab mouse 5T4 non-small cell lung carcinoma, renal cell carcinoma
Narnatumab[65] mab human RON cancer
Natalizumab Tysabri mab humanized integrin α4 multiple sclerosis, Crohn's disease
Nebacumab mab human endotoxin sepsis
Necitumumab[66] mab human EGFR non-small cell lung carcinoma
Nerelimomab mab mouse TNF-α  ?
Nimotuzumab[26][67] Theracim, Theraloc mab humanized EGFR squamous cell carcinoma, head and neck cancer, nasopharyngeal cancer, glioma
Nofetumomab merpentan Verluma Fab mouse  ? cancer (diagnosis)
Ocrelizumab[26] mab humanized CD20 rheumatoid arthritis, lupus erythematosus etc.
Odulimomab mab mouse LFA-1 (CD11a) prevention of organ transplant rejections, immunological diseases
Ofatumumab[13] Arzerra mab human CD20 chronic lymphocytic leukemia etc.
Olaratumab mab human PDGF-R α cancer
Olokizumab[46] mab humanized IL6  ?
Omalizumab[35] Xolair mab humanized IgE Fc region allergic asthma
Onartuzumab[68] mab humanized human scatter factor receptor kinase cancer
Oportuzumab monatox[66] scFv humanized EpCAM cancer
Oregovomab[38] OvaRex mab mouse CA-125 ovarian cancer
Otelixizumab[5] mab chimeric/humanized CD3 diabetes mellitus type 1
Oxelumab[69] mab human OX-40 asthma
Ozoralizumab[70] mab humanized Lama glama inflammation
Pagibaximab[13] mab chimeric lipoteichoic acid sepsis (Staphylococcus)
Palivizumab Synagis, Abbosynagis mab humanized respiratory syncytial virus respiratory syncytial virus (prevention)
Panitumumab[37] Vectibix mab human EGFR colorectal cancer
Panobacumab[66] mab human Pseudomonas aeruginosa Pseudomonas aeruginosa infection
Pascolizumab[10] mab humanized IL-4 asthma
Pateclizumab[15] mab humanized LTA TNF
Patritumab[20] mab human HER3 cancer
Pemtumomab Theragyn  ? mouse MUC1 cancer
Pertuzumab Omnitarg mab humanized HER2/neu cancer
Pexelizumab[29] scFv humanized C5 reduction of side effects of cardiac surgery
Pintumomab mab mouse adenocarcinoma antigen adenocarcinoma (imaging)
Ponezumab[71] mab humanized human beta-amyloid Alzheimer's disease
Priliximab mab chimeric CD4 Crohn's disease, multiple sclerosis
Pritumumab mab human vimentin brain cancer
PRO 140  ? humanized CCR5 HIV infection
Quilizumab[20] mab humanized IGHE  ?
Racotumomab[66] mab mouse N-glycolylneuraminic acid cancer
Radretumab[12] mab human fibronectin extra domain-B cancer
Rafivirumab[4] mab human rabies virus glycoprotein rabies (prophylaxis)
Ramucirumab mab human VEGFR2 solid tumors
Ranibizumab[3] Lucentis Fab humanized VEGF-A macular degeneration (wet form)
Raxibacumab[14] mab human anthrax toxin, protective antigen anthrax (prophylaxis and treatment)
Regavirumab mab human cytomegalovirus glycoprotein B cytomegalovirus infection
Reslizumab[29] mab humanized IL-5 inflammations of the airways, skin and gastrointestinal tract
Rilotumumab[72] mab human HGF solid tumors
Rituximab MabThera, Rituxan mab chimeric CD20 lymphomas, leukemias, some autoimmune disorders
Robatumumab mab human IGF-1 receptor cancer
Roledumab[46] mab human RHD  ?
Romosozumab[73] mab humanized scleroscin osteoporosis
Rontalizumab[74] mab humanized IFN-α systemic lupus erythematosus
Rovelizumab LeukArrest mab humanized CD11, CD18 haemorrhagic shock etc.
Ruplizumab[7] Antova mab humanized CD154 (CD40L) rheumatic diseases
Samalizumab[75] mab humanized CD200 cancer
Sarilumab[76] mab human IL6 rheumatoid arthritis, ankylosing spondylitis
Satumomab pendetide mab mouse TAG-72 cancer (diagnosis)
Secukinumab[77] mab human IL-17A uveitis, rheumatoid arthritis psoriasis
Sevirumab  ? human cytomegalovirus cytomegalovirus infection
Sibrotuzumab mab humanized FAP cancer
Sifalimumab[78] mab humanized IFN-α SLE, dermatomyositis, polymyositis
Siltuximab mab chimeric IL-6 cancer
Siplizumab[10] mab humanized CD2 psoriasis, graft-versus-host disease (prevention)
Sirukumab[79] mab human IL-6 rheumatoid arthritis
Solanezumab[66] mab humanized beta amyloid Alzheimer's disease
Solitomab[20] mab mouse EPCAM  ?
Sonepcizumab[80]  ? humanized sphingosine-1-phosphate choroidal and retinal neovascularization
Sontuzumab[67] mab humanized episialin  ?
Stamulumab[26][67] mab human myostatin muscular dystrophy
Sulesomab LeukoScan Fab' mouse NCA-90 (granulocyte antigen) osteomyelitis (imaging)
Suvizumab[52] mab humanized HIV-1 viral infections
Tabalumab[81] mab human BAFF B-cell cancers
Tacatuzumab tetraxetan AFP-Cide mab humanized alpha-fetoprotein cancer
Tadocizumab[67] Fab humanized integrin αIIbβ3 percutaneous coronary intervention
Talizumab mab humanized IgE allergic reaction
Tanezumab[4] mab humanized NGF pain
Taplitumomab paptox[35] mab mouse CD19 cancer[citation needed]
Tefibazumab[14] Aurexis mab humanized clumping factor A Staphylococcus aureus infection
Telimomab aritox Fab mouse  ?  ?
Tenatumomab[5] mab mouse tenascin C cancer
Teneliximab[10] mab chimeric CD40  ?
Teplizumab[19] mab humanized CD3 diabetes mellitus type 1
Teprotumumab[82] mab human CD221 hematologic tumors
TGN1412  ? humanized CD28 chronic lymphocytic leukemia, rheumatoid arthritis
Ticilimumab (= tremelimumab) mab human CTLA-4 cancer
Tigatuzumab[5] mab humanized TRAIL-R2 cancer
TNX-650  ? humanized IL-13 Hodgkin's lymphoma
Tocilizumab[3] (= atlizumab) Actemra, RoActemra mab humanized IL-6 receptor rheumatoid arthritis
Toralizumab[10] mab humanized CD154 (CD40L) rheumatoid arthritis, lupus nephritis etc.
Tositumomab Bexxar  ? mouse CD20 follicular lymphoma
Tralokinumab[83] mab human IL-13 asthma etc.
Trastuzumab Herceptin mab humanized HER2/neu breast cancer
TRBS07[84] Ektomab 3funct  ? GD2 melanoma
Tregalizumab[12] mab humanized CD4  ?
Tremelimumab mab human CTLA-4 cancer
Tucotuzumab celmoleukin[26][67] mab humanized EpCAM cancer
Tuvirumab  ? human hepatitis B virus chronic hepatitis B
Ublituximab[12] mab chimeric MS4A1 cancer
Urelumab[85] mab human 4-1BB cancer etc.
Urtoxazumab[3] mab humanized Escherichia coli diarrhoea caused by E. coli
Ustekinumab[4] Stelara mab human IL-12, IL-23 multiple sclerosis, psoriasis, psoriatic arthritis
Vapaliximab[10] mab chimeric AOC3 (VAP-1)  ?
Vatelizumab[15] mab humanized ITGA2  ?
Vedolizumab mab humanized integrin α4β7 Crohn's disease, ulcerative colitis
Veltuzumab[5] mab humanized CD20 non-Hodgkin's lymphoma
Vepalimomab mab mouse AOC3 (VAP-1) inflammation
Vesencumab[12] mab human NRP1  ?
Visilizumab[35] Nuvion mab humanized CD3 Crohn's disease, ulcerative colitis
Volociximab[13] mab chimeric integrin α5β1 solid tumors
Votumumab HumaSPECT mab human tumor antigen CTAA16.88 colorectal tumors
Zalutumumab[13] HuMax-EGFr mab human EGFR squamous cell carcinoma of the head and neck
Zanolimumab[3] HuMax-CD4 mab human CD4 rheumatoid arthritis, psoriasis, T-cell lymphoma
Ziralimumab[35] mab human CD147 (basigin)  ?
Zolimomab aritox mab mouse CD5 systemic lupus erythematosus, graft-versus-host disease

[edit] References

  1. ^ a b "United Therapeutics 10-K report". http://www.sec.gov/Archives/edgar/data/1082554/000104746911001229/a2202121z10-k.htm#da77001_item_1._business. Retrieved 5 November 2011. 
  2. ^ a b c d e World Health Organization (2006). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 95" (PDF). WHO Drug Information 20 (2). http://whqlibdoc.who.int/druginfo/20_2_2006_INN95.pdf. 
  3. ^ a b c d e f g World Health Organization (2004). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 90" (PDF). WHO Drug Information 18 (1). http://whqlibdoc.who.int/druginfo/18_1_2004_INN90.pdf. 
  4. ^ a b c d e f g World Health Organization (2008). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 99" (PDF). WHO Drug Information 22 (2). http://www.who.int/entity/medicines/publications/druginformation/issues/INN-PList-No99.pdf. 
  5. ^ a b c d e f g h i World Health Organization (2007). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 98" (PDF). WHO Drug Information 21 (4). http://www.who.int/medicines/publications/druginformation/innlists/P-List98.pdf. 
  6. ^ "BMS Shells Out $85M Up Front for Alder’s Mid-Stage Rheumatoid Arthritis Antibody". Genetic Engineering & Biotechnology News. 10 November 2009. http://www.genengnews.com/news/bnitem.aspx?name=68068627&source=genwire. 
  7. ^ a b c d World Health Organization (2000). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 83" (PDF). WHO Drug Information 14 (2). http://whqlibdoc.who.int/druginfo/DRUG_INFO_14_2_2000_INN-83.pdf. 
  8. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Amatuximab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/amatuximab.pdf. 
  9. ^ "Wyeth.com | Complete Project Listing". Wyeth. 2008. Archived from the original on June 12, 2008. http://web.archive.org/web/20080612044330/http://www.wyeth.com/research/projects. Retrieved November 19, 2008. 
  10. ^ a b c d e f g h i World Health Organization (2002). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 87" (PDF). WHO Drug Information 16 (2). http://whqlibdoc.who.int/druginfo/16_2_2002_INN87.pdf. 
  11. ^ a b c World Health Organization (2003). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 88" (PDF). WHO Drug Information 17 (1). http://whqlibdoc.who.int/druginfo/17_1_2003_INN88.pdf. 
  12. ^ a b c d e f World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104" (PDF). WHO Drug Information 24 (4). http://www.who.int/medicines/publications/druginformation/innlists/Final_PL104.pdf. 
  13. ^ a b c d e f g h World Health Organization (2008). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 93" (PDF). WHO Drug Information 19 (2). http://whqlibdoc.who.int/druginfo/19_2_2005_INN93.pdf. 
  14. ^ a b c d World Health Organization (2004). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 92" (PDF). WHO Drug Information 18 (4). http://whqlibdoc.who.int/druginfo/18_4_2004_INN92.pdf. 
  15. ^ a b c d e World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF). WHO Drug Information 25 (2). http://www.who.int/medicines/publications/druginformation/innlists/Final_PL105.pdf. 
  16. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Brentuximab vedotin". American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/brentuximab-vedotin.pdf. 
  17. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Briakinumab". American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/briakinumab.pdf. 
  18. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Brodalumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/brodalumab.pdf. 
  19. ^ a b c d World Health Organization (2007). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 97" (PDF). WHO Drug Information 21 (2). http://whqlibdoc.who.int/druginfo/21_2_2007_INN97.pdf. 
  20. ^ a b c d e World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106" (PDF). WHO Drug Information 25 (4). http://www.who.int/medicines/publications/druginformation/innlists/Final_PL106.pdf. 
  21. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Carlumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/carlumab.pdf. 
  22. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Yttrium Y90 clivatuzumab tetraxetan". American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/yttrium-Y-90-clivatuzumab-tetraxetan.pdf. 
  23. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Crenezumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/crenezumab.pdf. 
  24. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Dalotuzumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/dalotuzumab.pdf. 
  25. ^ a b World Health Organization (2009). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 101" (PDF). WHO Drug Information 23 (2). http://whqlibdoc.who.int/druginfo/23_2_2009_INN101.pdf. 
  26. ^ a b c d e f g World Health Organization (2005). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 94" (PDF). WHO Drug Information 19 (4). http://whqlibdoc.who.int/druginfo/19_4_2005_INN94.pdf. 
  27. ^ World Health Organization (1991). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 66" (PDF). WHO Drug Information 5 (4). http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list66.pdf. 
  28. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Drozitumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/drozitumab.pdf. 
  29. ^ a b c d World Health Organization (2001). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 85" (PDF). WHO Drug Information 15 (2). http://whqlibdoc.who.int/druginfo/DRUG_INFO_15_2_2001_INN-85.pdf. 
  30. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Enavatuzumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/enavatuzumab.pdf. 
  31. ^ World Health Organization (1997). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 77" (PDF). WHO Drug Information 11 (2). http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list77.pdf. 
  32. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Enokizumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/enokizumab.pdf. 
  33. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ensituximab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/ensituximab.pdf. 
  34. ^ World Health Organization (2004). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 51" (PDF). WHO Drug Information 18 (1). http://whqlibdoc.who.int/druginfo/INN_2004_list51.pdf. 
  35. ^ a b c d e f g World Health Organization (2000). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 84" (PDF). WHO Drug Information 14 (4). http://whqlibdoc.who.int/druginfo/DRUG_INFO_14_4_2000_INN-84.pdf. 
  36. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Etrolizumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/etrolizumab.pdf. 
  37. ^ a b c d World Health Organization (2004). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 91" (PDF). WHO Drug Information 18 (2). http://whqlibdoc.who.int/druginfo/18_2_2004_INN91.pdf. 
  38. ^ a b c World Health Organization (2002). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 86" (PDF). WHO Drug Information 16 (12). http://whqlibdoc.who.int/druginfo/16_1_2002_INN86.pdf. 
  39. ^ Buhmann, R; et al, B; Stanglmaier, M; Yang, T; Faltin, M; Bund, D; Lindhofer, H; Kolb, HJ (2008). "Immunotherapy of recurrent B–cell malignancies after allo SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion". Bone Marrow Transplantation 43 (5): 383–397. doi:10.1038/bmt.2008.323. PMID 18850012. 
  40. ^ Boehrer, S; et al, Petra; Mueller, Tina; Atz, Judith; Chow, Kai Uwe (2011). "Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanisms". Anti-Cancer Drugs 12 (10): 3085–3091. doi:10.1097/CAD.0b013e328344887f. http://journals.lww.com/anti-cancerdrugs/Abstract/publishahead/Cytotoxic_effects_of_the_trifunctional_bispecific.99702.aspx. 
  41. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Fezakinumab". American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/fezakinumab.pdf. 
  42. ^ ClinicalTrials.gov NCT00883896 Study to Evaluate the Safety and Efficacy of ILV-094 in Subjects With Rheumatoid Arthritis
  43. ^ ClinicalTrials.gov NCT00563524 Study Evaluating the Safety and Tolerability of ILV-094 in Subjects With Psoriasis
  44. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ficlatuzumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/ficlatuzumab.pdf. 
  45. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Flanvotumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/flanvotumab.pdf. 
  46. ^ a b c d World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 103" (PDF). WHO Drug Information. http://www.who.int/medicines/publications/druginformation/INN_PL103.pdf. 
  47. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Fresolimumab". American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/fresolimumab.pdf. 
  48. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Fulranumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/fulranumab.pdf. 
  49. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ganitumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/ganitumab.pdf. 
  50. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Gevokizumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/gevokizumab.pdf. 
  51. ^ http://www.prnewswire.com/news-releases/prometheus-obtains-exclusive-us-commercialization-rights-for-rencarex-121075044.html
  52. ^ a b World Health Organization (2009). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 102" (PDF). WHO Drug Information 23 (4). http://www.who.int/medicines/services/inn/FINAL_PL102.pdf. 
  53. ^ NCI Drug Dictionary: Glemtumumab vedotin
  54. ^ "Gilead Sciences 10-K report". http://edgar.sec.gov/Archives/edgar/data/882095/000119312511050041/d10k.htm. Retrieved 5 November 2011. 
  55. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Icrucumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/icrucumab.pdf. 
  56. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Intetumumab". American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/intetumumab.pdf. 
  57. ^ ClinicalTrials.gov NCT00537381 A Study of the Safety and Effectiveness of CNTO 95 in Patients With Metastatic Hormone Refractory Prostate Cancer
  58. ^ ClinicalTrials.gov NCT00246012 A Study of the Safety and Efficacy CNTO 95 in Subjects With Advanced Melanoma
  59. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ixekizumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/ixekizumab.pdf. 
  60. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Lebrikizumab". American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/lebrikizumab.pdf. 
  61. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Mavrilimumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/mavrilimumab.pdf. 
  62. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Mogamulizumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/mogamulizumab.pdf. 
  63. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Moxetumomab Pasudotox". American Medical Association. http://www.ama-assn.org/resources/doc/usan/moxetumomab-pasudotox.pdf. 
  64. ^ World Health Organization (2006). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 96" (PDF). WHO Drug Information 20 (4). http://whqlibdoc.who.int/druginfo/20_4_2006_INN96.pdf. 
  65. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Narnatumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/narnatumab.pdf. 
  66. ^ a b c d e World Health Organization (2008). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 100 (prepublication copy)" (PDF). WHO Drug Information. http://www.who.int/entity/medicines/publications/druginformation/innlists/PL100prepubli.pdf. 
  67. ^ a b c d e World Health Organization (2006). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 56" (PDF). WHO Drug Information 20 (3). http://whqlibdoc.who.int/druginfo/INN_2006_list56.pdf. 
  68. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Onartuzumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/onartuzumab.pdf. 
  69. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Oxelumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/oxelumab.pdf. 
  70. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ozoralizumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/ozoralizumab.pdf. 
  71. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ponezumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/ponezumab.pdf. 
  72. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Rilotumumab". American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/rilotumumab.pdf. 
  73. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Romosozumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/romosozumab.pdf. 
  74. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Rontalizumab". American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/rontalizumab.pdf. 
  75. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Samalizumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/samalizumab.pdf. 
  76. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sarilumab". American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/sarilumab.pdf. 
  77. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Secukinumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/secukinumab.pdf. 
  78. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sifalimumab". American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/sifalimumab.pdf. 
  79. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sirukumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/sirukumab.pdf. 
  80. ^ Xie, B.; Shen, J.; Dong, A.; Rashid, A.; Stoller, G.; Campochiaro, P. A. (2009). "Blockade of Sphingosine-1-phosphate Reduces Macrophage Influx and Retinal and Choroidal Neovascularization". Journal of Cellular Physiology 218 (1): 192–198. doi:10.1002/jcp.21588. PMC 2905312. PMID 18781584. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2905312.  edit
  81. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Tabalumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/tabalumab.pdf. 
  82. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Teprotumumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/teprotumumab.pdf. 
  83. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Tralokinumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/tralokinumab.pdf. 
  84. ^ Ruf, P; et al, M; Ellwart, J; Wosch, S; Kusterer, E; Lindhofer, H (2004). "Two new trifunctional antibodies for the therapy of human malignant melanoma". International Journal of Cancer 108 (5): 725–732. doi:10.1002/ijc.11630. PMID 14696099. 
  85. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Urelumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/urelumab.pdf. 
Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems
Bone ("-os-", "-s(o)-")
Human ("-osu-")
Humanized ("-sozu-")
Musculoskeletal ("-mul-")
Human ("-mulu-")
Circulatory ("-c(i[r])-")
Human ("-ciru-")
Mouse ("-ciro-")
Biciromab‡ • Imciromab‡
Chimeric ("-cixi-")
Humanized ("-cizu-")
Neurologic ("-ne(u)(r)-")
Human ("-neru-")
Humanized ("-nezu-"/"-neuzu-")
Angiogenesis inhibitor ("-anibi-")
Humanized ("-anibizu-")
Immune system ("-l(i[m])-")
Human ("-limu-")
Mouse ("-limo-")
Chimeric ("-lixi-")
Humanized ("-lizu-")
Chimeric + humanized
("-lixizu-")
Interleukin ("-k(i[n])-")
Human ("-kinu-")
Humanized ("-kizu-", "-kinzu-")
Inflammatory lesions ("-les-")
Mouse ("-leso-")
Fungal ("-fung-")
Human ("-fungu-")
Viral ("-vi(r)-")
Human ("-viru-")
Humanized ("-vizu-")
Bacterial ("-ba(c)-")
Human ("-bacu-")
Mouse ("-baco-")
Chimeric ("-baxi-")
Humanized ("-bazu-")
Toxin ("-tox(a)-")
Humanized ("-toxazu-")
Tumor ("-t(u[m])-")
Human ("-tumu-")
Mouse ("-tumo-")
Chimeric ("-tuxi-")
Humanized ("-tuzu-")
Rat/mouse hybrid ("-tumaxo-")
Whole antibody
Engineered monoclonal antibodies.svg
Fab fragment
Variable fragment
Smaller units
Intracellular
Antibody mimetics
Retrieved from "http://en.wikipedia.org/w/index.php?title=List_of_monoclonal_antibodies&oldid=472239513"
Personal tools
Namespaces
Variants
Actions
Navigation
Interaction
Toolbox
Print/export
Languages